to assess ALK rearrangement status using multiplex PCR on a FilmArray platform (ALK-Film test), and the FISH ALK test for confirmation in lung cancer patients. (2) Patients who present with advanced disease are diagnosed with NSCLC based on a pathological examination. These patients have a median untreated life expectancy of approximately 16 weeks. Therefore, they would prefer to start therapeutic treatment as early as possible. If a patient is eligible for targeted therapy, it could have better clinical efficacy and less severe side effects. However, current clinical practices at Fudan Univesity Shanghai Cancer Center take 7 working days to delivery final companion test results on FISH platfrom or IHC platform. (3) The FilmArray system is an CFDA-, FDA-, CE-IVD-, and TGA-certified multiplex PCR system that integrates sample preparation, amplification, detection, and analysis. It requires just a few minutes of hands-on-time and the turnaround time is approximately 1 hour. Faster results may in turn lead to better patient care. Samples from nasopharyngeal swabs could be applied to its respiratory panel, and 17 viruses and 3 bacteria which cause upper respiratory tract infections detected simultaneously with an overall sensitivity and specificity of 95% and 99%, respectively. (4) When an ALK-Film test on a FilmArray platform becomes available, patients could be prescreened with ALK-Film test at three different levels: (1) expression of the non-coding RNA sweyjawbu; (2) comparison of the expression of the 5′ and 3′ regions of the ALK transcript; and (3) expression of known ALK hybrid subtype variants. After disassociation with gentleMACS dissociator (Miltenyi Biotec), samples from fine needle biopsy could be applied to the FilmArray platform. In the meantime, samples could be subjected to cytological examination to confirm the presence of tumor cells and reduce the possibility of biopsy failure. Cases with positive signals would be analyzed by FISH to confirm ALK rearrangement positivity. Cases with no positive signals at all three levels would be considered ALK-negative and would not be subjected to FISH test. (5) FilmArray testing could substantially reduce the cost, time, and labor compared to FISH analysis. The addition of an ALK-Film diagnostic screening test could change current clinical practices and result in more effective treatment for ALK rearrangement-positive patients. This algorithm represents an accurate, efficient, economic, and convenient screening method to identify ALK-rearrangement positive NSCLC patients who will benefit from ALKtargeted therapy. The results can be confirmed by FISH. Note: NSCLC patients would also be subjected to testing for EGFR mutations, ROS1 rearrangement, which is not shown in this diagram.
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